BR112022008031A2 - Formulações de pó seco de anticorpos de ligação à linfopoietina estromal tímica (tslp) e métodos de uso das mesmas - Google Patents
Formulações de pó seco de anticorpos de ligação à linfopoietina estromal tímica (tslp) e métodos de uso das mesmasInfo
- Publication number
- BR112022008031A2 BR112022008031A2 BR112022008031A BR112022008031A BR112022008031A2 BR 112022008031 A2 BR112022008031 A2 BR 112022008031A2 BR 112022008031 A BR112022008031 A BR 112022008031A BR 112022008031 A BR112022008031 A BR 112022008031A BR 112022008031 A2 BR112022008031 A2 BR 112022008031A2
- Authority
- BR
- Brazil
- Prior art keywords
- dry powder
- tslp
- powder formulations
- methods
- thymic stromal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
FORMULAÇÃO DE PÓ SECO ANTECORPOS DE LIGAÇÃO À LINFOPOIETINA ESTROMAL TÍMICA (TSLP) E MÉTODO PARA USO DAS MESMAS. A presente tecnologia refere-se geralmente a formulações de pó seco de anticorpos específicos para linfopoietina estromal tímica (TSLP), bem como métodos para tratar asma, usando as formulações de pó seco, adequadamente via distribuição pulmonar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962926833P | 2019-10-28 | 2019-10-28 | |
PCT/EP2020/080201 WO2021083908A1 (en) | 2019-10-28 | 2020-10-27 | Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022008031A2 true BR112022008031A2 (pt) | 2022-07-12 |
Family
ID=73030137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022008031A BR112022008031A2 (pt) | 2019-10-28 | 2020-10-27 | Formulações de pó seco de anticorpos de ligação à linfopoietina estromal tímica (tslp) e métodos de uso das mesmas |
Country Status (16)
Country | Link |
---|---|
US (2) | US11904053B2 (pt) |
EP (1) | EP4051708A1 (pt) |
JP (1) | JP2022554249A (pt) |
KR (1) | KR20220088752A (pt) |
CN (1) | CN114867748A (pt) |
AR (1) | AR120309A1 (pt) |
AU (1) | AU2020376222A1 (pt) |
BR (1) | BR112022008031A2 (pt) |
CA (1) | CA3154999A1 (pt) |
CL (1) | CL2023003432A1 (pt) |
CO (1) | CO2022005391A2 (pt) |
CR (1) | CR20220189A (pt) |
IL (1) | IL292437A (pt) |
MX (1) | MX2022005083A (pt) |
TW (1) | TW202131947A (pt) |
WO (1) | WO2021083908A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024516962A (ja) * | 2021-04-19 | 2024-04-18 | メドイミューン・リミテッド | 安定性が改善された抗TSLP Fab |
US20230270668A1 (en) * | 2021-10-11 | 2023-08-31 | Augmenta Bioworks, Inc. | Dry formulations of anti-sars-cov-2 virus antibodies and compositions and methods of use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1666028T3 (da) | 1999-10-29 | 2010-06-21 | Novartis Ag | Tørre pulversammensætninger med forbedret dispersitet |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
WO2016142426A1 (en) * | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | Tslp binding proteins |
UY36889A (es) * | 2015-09-09 | 2017-04-28 | Novartis Ag | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas |
RU2731212C2 (ru) * | 2015-09-09 | 2020-08-31 | Новартис Аг | Направленная доставка высушенных распылением композиций в легкие |
MX2018003038A (es) * | 2015-09-09 | 2018-04-11 | Novartis Ag | Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas. |
JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
WO2019145897A1 (en) | 2018-01-26 | 2019-08-01 | Novartis Ag | High dose delivery of inhaled therapeutics |
-
2020
- 2020-10-27 CN CN202080086052.9A patent/CN114867748A/zh active Pending
- 2020-10-27 US US17/081,821 patent/US11904053B2/en active Active
- 2020-10-27 AU AU2020376222A patent/AU2020376222A1/en active Pending
- 2020-10-27 KR KR1020227017241A patent/KR20220088752A/ko unknown
- 2020-10-27 EP EP20797753.9A patent/EP4051708A1/en active Pending
- 2020-10-27 CR CR20220189A patent/CR20220189A/es unknown
- 2020-10-27 AR ARP200102963A patent/AR120309A1/es unknown
- 2020-10-27 WO PCT/EP2020/080201 patent/WO2021083908A1/en unknown
- 2020-10-27 CA CA3154999A patent/CA3154999A1/en active Pending
- 2020-10-27 JP JP2022525006A patent/JP2022554249A/ja active Pending
- 2020-10-27 IL IL292437A patent/IL292437A/en unknown
- 2020-10-27 BR BR112022008031A patent/BR112022008031A2/pt unknown
- 2020-10-27 MX MX2022005083A patent/MX2022005083A/es unknown
- 2020-10-28 TW TW109137435A patent/TW202131947A/zh unknown
-
2022
- 2022-04-28 CO CONC2022/0005391A patent/CO2022005391A2/es unknown
- 2022-11-09 US US18/053,941 patent/US20230201120A1/en active Pending
-
2023
- 2023-11-19 CL CL2023003432A patent/CL2023003432A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL292437A (en) | 2022-06-01 |
KR20220088752A (ko) | 2022-06-28 |
CO2022005391A2 (es) | 2022-08-19 |
US20210121406A1 (en) | 2021-04-29 |
CR20220189A (es) | 2022-08-19 |
MX2022005083A (es) | 2022-07-19 |
AU2020376222A1 (en) | 2022-06-02 |
CL2023003432A1 (es) | 2024-05-17 |
US20230201120A1 (en) | 2023-06-29 |
EP4051708A1 (en) | 2022-09-07 |
CA3154999A1 (en) | 2021-05-06 |
US11904053B2 (en) | 2024-02-20 |
WO2021083908A1 (en) | 2021-05-06 |
AR120309A1 (es) | 2022-02-09 |
JP2022554249A (ja) | 2022-12-28 |
CN114867748A (zh) | 2022-08-05 |
TW202131947A (zh) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20200484A1 (es) | Tratamiento para el asma con anticuerpo anti-tslp | |
CO2022005391A2 (es) | Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos | |
CL2017003226A1 (es) | Reguladores nrf2 | |
CO2018002446A2 (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
MX2021014700A (es) | Variantes de vector del virus asociado a adeno para edicion genomica de alta eficacia y sus metodos. | |
ECSP18023386A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
WO2012051629A3 (en) | Compositions and methods for treating keratin based fibers | |
BR112017014230A2 (pt) | endófitos de semente através de cultivares e espécies, composições associadas e métodos de uso dos mesmos | |
CL2011003273A1 (es) | Antígeno del virus respiratorio sincicial (vrs) recombinante, que comprende un polipéptido de proteína f soluble con una modificación que altera su glicosilación y que a su vez comprende un dominio f1 y un dominio f2 de proteína f de vrs; composición inmunogénica que lo comprende; ácido nucleico que lo codifica; vector; célula hospedera; método para producir dicho antígeno del vrs; y su uso para tratar una infección de vrs. | |
CL2008002015A1 (es) | Anticuerpo anti-receptor del factor de creciemiento de hepatocito (hgf)/receptor c-met; hibridoma que lo produce; acido nucleico que lo codifica; vector y celula huesped que los comprende; procedimiento de produccion; composicion que los comprende; su uso para tratar cancer; y metodo de diagnostico in vitro | |
BR112013008700B8 (pt) | Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante | |
UY37279A (es) | Anticuerpos tgf-beta y fragmentos de unión de los mismos | |
DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
BR112019013005A2 (pt) | espécie de metschnikowia isolada, método para produzir xilitol, xilitol bioderivado e composição | |
ECSP17075380A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
BR112017001696A2 (pt) | composições de célula-tronco e métodos de produção de células-tronco para aplicações terapêuticas | |
BR112016024635A2 (pt) | meios de crescimento microbiológico e métodos de uso do mesmo | |
BR112016005509A8 (pt) | método de preparação de um extrato de sementes de urucum (anato), composição, extrato vegetal, e composição farmacêutica | |
UY34322A (es) | ?compuestos reguladores del crecimiento vegetal, método para su aplicación y uso de dichos compuestos?. | |
BR112012032050A2 (pt) | fotoiniciador polimérico, método para o fabrico de uma composição matriz reticulada, composição matriz reticulada, e, uso do fotoiniciador polimérico | |
BR112018005464A2 (pt) | expressão de proteínas contendo fc | |
CA2899426C (en) | Use of 3.3'-thiodipropionic acid and derivatives thereof to repair damaged hair | |
MX2015017796A (es) | Preparacion de particulas secas que comprenden mentol. | |
MX2016017136A (es) | Composiciones y metodos para detectar pegivirus 2 de humano (hpgv-2). |